Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.

E. Marleen Kemper(Amsterdam University Medical Centers), Olaf van Tellingen(Dutch Cancer Society), A Erik van Zandbergen, Cindy G. J. Cleypool, Jos H. Beijnen(The Netherlands Cancer Institute), Henk A Mos, Willem Boogerd(The Netherlands Cancer Institute)
PubMed
July 1, 2003
Cited by 242

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884
Impairment of Cognitive Function in Women Receiving Adjuvant Treatment for High-Risk Breast Cancer: High-Dose Versus Standard-Dose Chemotherapy
|JNCI Journal of the National Cancer Institute|1998|768